Assembly Actions -
Senate Actions - UPPERCASE
|May 04, 2020||
referred to health
Assembly Bill A10385
2019-2020 Legislative Session
Archive: Last Bill Status - In Assembly Committee
- In Committee Assembly
- On Floor Calendar Assembly
- Passed Assembly
- Delivered to Governor
- Signed By Governor
2019-A10385 (ACTIVE) - Details
2019-A10385 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 10385 I N A S S E M B L Y May 4, 2020 ___________ Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Health AN ACT in relation to determining whether the state can claim federal financial participation for coverage of and payment for certain prescription digital therapeutics THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative finding and declaration. New Yorkers in recov- ery for substance and opioid use disorders and in treatment for mental health conditions are losing access to in-person treatment under the state's "stay at home" and social distancing orders as part of coronavi- rus pandemic mitigation efforts. In recent news reports, experts warn that the coronavirus pandemic may be "a national relapse trigger" for individuals in treatment for alcohol, cocaine, methamphetamine, marijua- na, and heroin addiction. Prescription Digital Therapeutics (PDTs) are new, software-based disease treatments designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. These therapies are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software. Certain PDTs provide clinicians and patients with evidence-based remote treatment modalities to treat substance and opioid use disorders, mental health, and other diseases and conditions. However, there is no clear statutory benefit category to allow Medicaid coverage for PDTs. In light of the promise of PDTs for the treatment of patients with substance use and opioid use disorders during the coronavirus pandemic, this legislation would require that the New York state department of health seek guidance from the Centers for Medicare and Medicaid Services relative to a coverage and reimbursement pathway for PDTs, in order to accelerate access to such therapies for enrollees. § 2. No later than 30 days from the effective date of this section, the New York state department of health shall request guidance from the Centers for Medicare and Medicaid Services to determine whether the EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.